Fenofibrate – 50 g

Brand:
Cayman
CAS:
49562-28-9
Storage:
-20
UN-No:
Non-Hazardous - /

Fenofibrate is an agonist of peroxisome proliferator-activated receptor α (PPARα) with EC50 values of 18 and 30 μM for mouse and human receptors, respectively, in a transactivation assay.{10670} It is selective for PPARα over PPARγ (EC50s = 300 and 200 μM for mouse and human receptors, respectively) and lacks activity at mouse and human PPARδ at a concentration of 100 μM. In vivo, fenofibrate (50-100 mg/kg) reduces plasma levels of triglycerides, C-reactive protein, and malondialdehyde (MDA) in mice with fructose-induced hypertriglycemia in a dose-dependent manner.{43262} It decreases glomerular and tubular atrophy and necrosis induced by cisplatin (Item No. 13119) in rat kidney when administered at a dose of 100 mg/kg.{43263} Fenofibrate also reduces the number of pulmonary lesions induced by 4-nitroquinoline 1-oxide (4-NQO) in lung in Tsumura Suzuki obese diabetic (TSOD) mice.{43264}  

 

Available on backorder

SKU: 10005368 - 50 g Category:

Description

A PPARα agonist (EC50s = 18 and 30 μM for mouse and human receptors, respectively, in a transactivation assay); selective for PPARα over PPARγ (EC50s = 300 and 200 μM for mouse and human receptors, respectively) and lacks activity at mouse and human PPARδ at 100 μM; reduces plasma levels of triglycerides, C-reactive protein, and MDA in mice with fructose-induced hypertriglycemia from 50-100 mg/kg; decreases cisplatin-induced glomerular and tubular atrophy and necrosis in rat kidney at 100 mg/kg; reduces the number of 4-NQO-induced pulmonary lesions in lung in TSOD mice


Formal name: 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester

Synonyms: 

Molecular weight: 360.8

CAS: 49562-28-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Cardiovascular System|Lipids & Lipoproteins||Research Area|Endocrinology & Metabolism|Hormones & Receptors|PPARs||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity